<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="66315">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02242565</url>
  </required_header>
  <id_info>
    <org_study_id>576424</org_study_id>
    <secondary_id>010-04-14</secondary_id>
    <nct_id>NCT02242565</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Different ShangRing Device Sizes for Adult Male Circumcision in Lusaka, Zambia</brief_title>
  <official_title>Safety and Effectiveness of Different ShangRing Device Sizes for Adult Male Circumcision in Lusaka, Zambia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Zambia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FHI 360</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety of ShangRing MMC procedures when providers
      choose among 7 adult sizes (reduced-sizes or treatment arm) versus the full range of 14
      adult sizes (all-sizes or control arm) during routine service delivery in Lusaka, Zambia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage and 95% confidence interval of men with at least one moderate or severe adverse event.</measure>
    <time_frame>42 days</time_frame>
    <description>To assess the safety of ShangRing procedures when providers choose among 7 adult sizes (reduced-sizes or treatment arm) versus the full range of 14 adult sizes (all-sizes or control arm) during routine service delivery in Lusaka, Zambia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of men who cannot be properly fitted with a ShangRing device</measure>
    <time_frame>42 days</time_frame>
    <description>Assess the effectiveness of ShangRing procedures in the reduced-sizes arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the acceptability of ShangRing procedures among participants and providers</measure>
    <time_frame>42 days</time_frame>
    <description>Participant acceptability (with procedure and cosmetic appearance), pain, and time to return to normal activity after ShangRing circumcision, overall and in each arm.
Provider acceptability assessing ease, duration, and complications, and preferences comparing ShangRing with other methods of circumcision, and comparing reduced-sizes with all-sizes provision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of men with complete healing at 42 days</measure>
    <time_frame>Day 42</time_frame>
    <description>Percentage of men with complete healing at 42 days for all study participants, and within each arm of the trial.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Male Circumcision</condition>
  <arm_group>
    <arm_group_label>Control: all-sizes of ShangRing</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All-sizes of ShangRings will be available.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced-sizes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 adult sizes of ShangRings will be available</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ShangRing</intervention_name>
    <description>ShangRing device for male circumcision</description>
    <arm_group_label>Control: all-sizes of ShangRing</arm_group_label>
    <arm_group_label>Reduced-sizes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be aged 18 to 49 years;

          -  Must be HIV-uninfected per same-day routine voluntary testing at the clinic;

          -  Must be uncircumcised (on examination);

          -  Must be in good general health, at the discretion of the clinician;

          -  Must be free of genital ulcerations or other visible signs of STI (on examination);

          -  Must be able to understand study procedures, and agree to abide by them including the
             follow-up visit schedule;

          -  Must freely consent to participate in the study and sign a written informed consent
             form;

          -  Must provide full contact information including cell phone number, address, and other
             locator information.

        Exclusion Criteria:

          -  Has an active genital infection upon visual inspection;

          -  Has an anatomic abnormality (e.g. phimosis or hypospadias) that contraindicates
             ShangRing MMC;

          -  Takes a medication that would be a contraindication for elective surgery, such as an
             anticoagulant or steroid; or

          -  Has a self-reported medical condition that would be a contraindication for elective
             surgery, e.g. hemophilia, extreme obesity, poorly controlled diabetes, sickle cell
             anemia

          -  Has a self-reported allergy or sensitivity to lidocaine or other local

          -  Is not available to be circumcised on the same day as screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Zulu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Teaching Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Feldblum, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FHI 360</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chilenje Urban Health Centre</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University Teaching Hospital (UTH)</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 16, 2016</lastchanged_date>
  <firstreceived_date>September 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV prevention</keyword>
  <keyword>ShangRing</keyword>
  <keyword>adverse events</keyword>
  <keyword>wound healing</keyword>
  <keyword>voluntary medical male circumcision (VMMC)</keyword>
  <keyword>medical device</keyword>
  <keyword>Zambia</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
